Open data sharing of the Parkinson’s Outcomes Project: A global, longitudinal clinical study of over 13,000 people with Parkinson’s disease
Objective: To describe the newly developed Parkinson’s Outcomes Project data sharing policy to the entire research community with a long-term goal of accelerating novel hypothesis…Interpretation of health-related quality of life outcomes from the EARLYSTIM Study
Objective: To conduct a secondary analysis of the EARLYSTIM study1 to 1: Quantify the meaning of HRQoL outcomes and 2: Evaluate the changes of disease…Transcutaneous magnetic spinal cord stimulation for freezing of gait in Parkinson’s disease (PD)
Objective: To study the safety and efficacy of transcutaneous magnetic spinal cord stimulation (SCS) on freezing of gait (FoG) and other motor symptoms in a…Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson’s Disease
Objective: To assess serum pharmacokinetics (PK) and cerebrospinal fluid (CSF) concentrations of nilotinib as well as CSF biomarker changes in NILO-PD study. Background: Several cell…Prospective assessment of the lessebo effect in placebo-controlled randomized trials using an expectancy questionnaire
Objective: To prospectively measure the lessebo effect using an expectancy questionnaire (EQ). Background: The presence of a placebo arm in a randomized controlled trial has…Cardiovascular Fitness, Plasma Biomarkers and Dopaminergic Denervation in Parkinson’s Disease
Objective: To examine the relationship between cardiovascular (CV) fitness, plasma biomarkers associated with PD progression and/or exercise and dopaminergic denervation, measured by I-123-Ioflupane single photon…Baseline results of a virtual longitudinal, observational study of Parkinson’s disease: The AT-HOME PD cohort
Objective: To describe the baseline characteristics of Parkinson’s disease (PD) clinical trial participants enrolled in a remote, long-term observational follow-up study. Background: Participation in clinical…CHIEF-PD: Cholinesterase Inhibitor to prEvent Falls in Parkinson’s Disease
Objective: Preventing falls in people with Parkinson’s disease has the potential to reduce hospital admissions and improve quality of life by diminishing the significant morbidity…Ampreloxetine (TD-9855), a long-acting, norepinephrine reuptake inhibitor (NRI) for the treatment of neurogenic orthostatic hypotension (nOH) in subjects with synucleinopathies: Phase 3 clinical program
Objective: To confirm: 1) clinical efficacy and safety of once-daily oral ampreloxetine in a 4-week double-blind (DB), placebo-controlled (PC) study (NCT03750552); 2) durability of efficacy…Serious games home rehabilitation program to treat gait and balance disorders in patients with Parkinson’s disease: A randomised controlled trial
Objective: To test the efficacy of an exergame rehabilitation programme at home to treat dopa-resistant gait and balance disorders in Parkinson’s disease (PD) patients. Background:…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.